Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.
Breaking News:
- Biometrics 3.0: When Devices Begin to Understand Us
- Tech Mahindra Advances AI-Driven Autonomous Network Operations for CSPs Globally with NVIDIA
- Loan of up to €13.7 million for Alumil Misr will expand manufacturing capacity and boost industrial competitiveness
- Panasonic Launches Green Impact Ramadan Campaign Promoting Sustainable Living Across the GCC
- ABC Supports the Beirut Fire Brigade in Recognition of Their Dedicated Service
- MAPFRE announces global rebrand
- Celebrate Ramadan with Immersive Experiences at Sharjah Collection
- Beauty Rituals from Ramadan to Eid at Privé7
Wednesday, March 4